Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.55 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.55 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.55 |
| ▸ | TXN | P10599 | 1/20 | 0.47 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909274 | 1.00 | EHMT2 (0.55) | EHMT2EHMT1APOBEC3GTXNTXNRD1 | |
| SCHEMBL2610936 | 0.86 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GTXNTXNRD1 | |
| SCHEMBL29533354 | 0.84 | EHMT2 (0.53) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL17583230 | 0.84 | EHMT2 (0.53) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL15301066 | 0.84 | EHMT2 (0.53) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL23775925 | 0.84 | EHMT2 (0.53) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL15301067 | 0.84 | EHMT2 (0.53) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL15912395 | 0.84 | EHMT2 (0.53) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL24393527 | 0.83 | EHMT2 (0.48) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL256693 | 0.81 | EHMT2 (0.48) | EHMT2EHMT1APOBEC3GTXNTXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361260-A1 | NUCLEOTIDE ANALOGUES | SINGULAR GENOMICS SYSTEMS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4380567-B1 | DISULFIDE COMPOUNDS AS MEDICAMENTS | CYTACOAT AB (SE) | 2025-05-07 | — | — | EP | disclosed |
| US-12215122-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240400602-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-12-05 | — | — | US | disclosed |
| US-12145960-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240316036-A1 | DISULFIDE CONTAINING THERAPEUTICS AND DIAGNOSTICS | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-09-26 | — | — | US | disclosed |
| US-20240269156-A1 | DISULFIDE CONTAINING THERAPEUTICS | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-08-15 | — | — | US | disclosed |
| US-20240174709-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-05-30 | — | — | US | disclosed |
| US-11958877-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| US-11878993-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2024-01-23 | — | — | US | disclosed |
| US-9096635-B2 | N-alkylthio beta-lactams, alkyl-coenzyme A asymmetric disulfides, and aryl-alkyl disulfides as anti-bacterial agents | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140322278-A1 | Modulation of Tissue Transglutaminase Activation in Disease | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140322278-A1 | Modulation of Tissue Transglutaminase Activation in Disease | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140235565-A1 | N-ALKYLTHIO BETA-LACTAMS, ALKYL-COENZYME A ASYMMETRIC DISULFIDES, AND ARYL-ALKYL DISULFIDES AS ANTI-BACTERIAL AGENTS | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235565-A1 | N-ALKYLTHIO BETA-LACTAMS, ALKYL-COENZYME A ASYMMETRIC DISULFIDES, AND ARYL-ALKYL DISULFIDES AS ANTI-BACTERIAL AGENTS | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-08-21 | — | — | US | disclosed |
| US-8722937-B2 | Asymmetric disulfides and aryl-alkyl disulfides as anti-bacterial agents | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-05-13 | — | — | US | disclosed |
| WO-2012177640-A2 | MODULATION OF TISSUE TRANSGLUTAMINASE ACTIVATION IN DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS (US) | 2010-01-28 | — | — | US | disclosed |
| US-20080182815-A1 | Act against several infective agents, and most notably Bacillus spp. and Staphylococcus spp., including infection caused by methicillin-resistant Staphylococcus aureus (MRSA) | UNIVERSITY OF SOUTH FLORIDA | 2008-07-31 | — | — | US | disclosed |
| US-20080182815-A1 | Act against several infective agents, and most notably Bacillus spp. and Staphylococcus spp., including infection caused by methicillin-resistant Staphylococcus aureus (MRSA) | UNIVERSITY OF SOUTH FLORIDA | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182815-A1 | Act against several infective agents, and most notably Bacillus spp. and Staphylococcus spp., including infection caused by methicillin-resistant Staphylococcus aureus (MRSA) | SQOR, TST, COASY | EHMT2 3558/4885EHMT1 3574/4885APOBEC3G 2997/4885 |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | EHMT2 4337/4885EHMT1 4185/4885APOBEC3G 2236/4885 |
| US-12215122-B2 | Nucleotide analogues | NUDT1, POLN, TYMP | EHMT2 2494/4885EHMT1 2450/4885APOBEC3G 226/4885 |
| US-20140322278-A1 | Modulation of Tissue Transglutaminase Activation in Disease | SI, TGM2, DSG1 | EHMT2 293/4885EHMT1 336/4885APOBEC3G 3532/4885 |
| US-20240400602-A1 | NUCLEOTIDE ANALOGUES | ADAR, NUDT1, NSUN2 | EHMT2 938/4885EHMT1 923/4885APOBEC3G 236/4885 |
| US-20240316036-A1 | DISULFIDE CONTAINING THERAPEUTICS AND DIAGNOSTICS | GPX1, GPX4, PDIA4 | EHMT2 2946/4885EHMT1 3031/4885APOBEC3G 4047/4885 |
| US-20250361260-A1 | NUCLEOTIDE ANALOGUES | ADAR, NUDT1, NSUN2 | EHMT2 938/4885EHMT1 923/4885APOBEC3G 236/4885 |
| US-20140235565-A1 | N-ALKYLTHIO BETA-LACTAMS, ALKYL-COENZYME A ASYMMETRIC DISULFIDES, AND ARYL-ALKYL DISULFIDES AS ANTI-BACTERIAL AGENTS | COASY, SQOR, TST | EHMT2 3650/4885EHMT1 3467/4885APOBEC3G 2560/4885 |
| US-20240269156-A1 | DISULFIDE CONTAINING THERAPEUTICS | P4HB, PDIA5, PDIA4 | EHMT2 3151/4885EHMT1 3191/4885APOBEC3G 2768/4885 |
| US-11958877-B2 | Nucleotide analogues | ITPA, POLB, NUDT1 | EHMT2 2878/4885EHMT1 3389/4885APOBEC3G 437/4885 |
| US-20240174709-A1 | NUCLEOTIDE ANALOGUES | NUDT1, POLN, TYMP | EHMT2 2494/4885EHMT1 2450/4885APOBEC3G 226/4885 |
| US-11878993-B2 | Nucleotide analogues | ITPA, POLB, NUDT1 | EHMT2 2878/4885EHMT1 3389/4885APOBEC3G 437/4885 |
| US-12145960-B2 | Nucleotide analogues | ITPA, POLB, NUDT1 | EHMT2 2878/4885EHMT1 3389/4885APOBEC3G 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.